Previous Webinar

Andrew Leach is head of Chemical Biology and head of Industry Partnerships at EMBL-EBI. His team develops and manages ChEMBL, EMBL-EBI’s database of quantitative small-molecule bioactivity data focused in the area of drug discovery. The group is involved in various other collaborative projects such as Open Targets and Illuminating the Druggable Genome, both of which are concerned with target selection and prioritization.

Tudor Oprea is Professor of Medicine, Pharmaceutical Sciences and Chemistry and Chemical Biology; and Division Chief, Translational Informatics, at the Department of Internal Medicine, University of New Mexico Health Sciences Center (New Mexico, USA); and Guest Professor at the universities of Gothenburg (Sweden) and Copenhagen (Denmark).

Melanie Schneider is a Protein Computational Scientist in the ChEMBL team at EMBL-EBI, Cambridge, UK. Her current research is focussed on the development of methods to assess target tractability, as part of the Open Targets consortium.

Brian Shoichet is Professor in the Department of Pharmaceutical Chemistry at UCSF. His lab seeks to discover chemical reagents that can illuminate biological problems by exploiting protein structures to predict new reagents and therapeutic leads (structure-based ligand discovery). A focus of his research is the discovery of reagents to modulate G-Protein Coupled Receptors (GPCRs).

Wendy Cornell is IBM Research Strategy Lead for Drug Discovery, responsible for guiding efforts across the IBM Research Labs to develop innovative capabilities for drug discovery and repurposing. In addition, she serves as Manager of the Yorktown Heights, NY-based Drug Discovery Technologies team, leading a group of simulation and AI experts in the development of next-generation tools to support small molecule and biologic design with an emphasis on exploiting protein structure and dynamic information. 

John Cuozzo is currently senior vice president in Drug Discovery at ZebiAI Therapeutics. ZebiAI Therapeutics is focused on applying machine learning (ML) at all stages of small molecule drug discovery to accelerate target validation and advance new therapeutics for unmet medical needs.

Kate Stafford is a senior scientist at Atomwise in the San Francisco bay area. She received her PhD from Columbia University and did her postdoctoral work at UCSF, and has been a part of the Atomwise cheminformatics team since 2017.